Analyst Coverage
Stock price graph

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Repros Therapeutics Inc.'s financial performance into perspective.

Recent Releases

Jul 17, 2017
Repros Announces Proellex® Development Program Will Remain on Partial Clinical Hold by the FDA

May 18, 2017
Repros Announces Pricing of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock

View all releases »

2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3446 fax